Ocata Therapeutics Company
%20.jpg)
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Founded Date:
1-1
Last Funding Type:
Venture - Series Unknown
Headquarters:
Marlborough, Massachusetts, United States
Investors Number:
13
Technology:
Regenerative Medicine
Employee Number:
11-50
Industry:
Biotechnology, Health Care, Therapeutics
Estimated Revenue:
$10M to $50M
Funding Status:
M&A
Investor Type:
For Profit
Total Funding:
$82.5M